📇 Rhumatologue ·

M Philippe MARTEAU

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Référence presse grand public
Cité 3 fois dans les médias — pédagogie reconnue

Rhumatologue

RPPS 10000382431

Enseignement

📊 Reconnaissance scientifique : 92/100📝 600 articles publiés🇫🇷 Publications académiques françaises (8)🎓 2 thèses dirigées

✨ Génération du profil synthétique IA en cours…

Direction de thèses

🎓 2 thèses dirigées

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study

Microbiome · 2020

📚 290 citations🎯 RCR 15.74Top 1% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background The role of the gut microbiota in Crohn’s disease (CD) is established and fecal microbiota transplantation (FMT) is an attractive therapeutic strategy. No randomized controlled clinical trial results are available. We performed a randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic CD. Method Patients enrolled while in flare received oral corticosteroid. Once in clinical remission, patients were randomized to receive either FMT or sham transplantation during a colonoscopy. Corticosteroids were tapered and a second colonoscopy was performed at week 6. The primary endpoint was the implantation of the donor microbiota at week 6 (Sorensen index > 0.6). Results Eight patients received FMT and nine sham transplantation. None of the patients reached the primary endpoint. The steroid-free clinical remission rate at 10 and 24 weeks was 44.4% (4/9) and 33.3% (3/9) in the sham transplantation group and 87.5% (7/8) and 50.0% (4/8; one patient loss of follow-up while in remission at week 12 and considered in flare at week 24) in the FMT group. Crohn’s Disease Endoscopic Index of Severity decreased 6 weeks after FMT (p = 0.03) but not after sham transplantation (p = 0.8). Conversely, the CRP level increased 6 weeks after sham transplantation (p = 0.008) but not after FMT (p = 0.5). Absence of donor microbiota engraftment was associated with flare. No safety signal was identified. Conclusion The primary endpoint was not reached for any patient. In this pilot study, higher colonization by donor microbiota was associated with maintenance of remission. These results must be confirmed in larger studies (NCT02097797).

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016

📚 169 citations🎯 RCR 7.41Top 4% NIH

Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group

The American journal of gastroenterology · 2017

📚 140 citations🎯 RCR 7.38Top 4% NIH

Cookies & analyse de trafic

M Philippe MARTEAU

Pourquoi vous devez consulter ce praticien

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (3)

Top publications · les plus citées

Publications scientifiques (36) — classées par pathologie

Transversal12

Microbiote5

Pharmacovigilance5

Anti-TNF4

Épidémiologie & registres4

Essai clinique3

Vraie vie / RWE3

Recommandations2

Activité physique / Rééducation1

Arthrite juvénile1

Gériatrie1

IA en rhumatologie1

Sjögren1

Datasets & protocoles partagés

Partager cette fiche